Literature DB >> 30860581

Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.

Jean-Daniel Lelièvre1,2,3.   

Abstract

Analytical treatment interruption performed during human immunodeficiency virus (HIV) cure-related clinical trials exposes sex partners of participants in these trials to a risk of HIV transmission. Preexposure prophylaxis (PrEP), which emerged in recent years as a key strategy for preventing HIV transmission, is often considered a useful tool to prevent this risk. This article supports offering PrEP to the stable sex partners of participants in these trials but also notes limitations that must be addressed. It concludes that PrEP cannot on its own eliminate the risk of secondary transmission in this context.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV; HIV transmission; PrEP; analytical treatment interruption

Mesh：

Substances：

Year:  2019        PMID： 30860581      PMCID： PMC6603967          DOI： 10.1093/infdis/jiz036

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  13 in total

1.  Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.

Authors:  Elske Hoornenborg; Maria Prins; Roel C A Achterbergh; Lycke R Woittiez; Marion Cornelissen; Suzanne Jurriaans; Neeltje A Kootstra; Peter L Anderson; Peter Reiss; Henry J C de Vries; Jan M Prins; Godelieve J de Bree
Journal:  Lancet HIV       Date:  2017-09-14       Impact factor: 12.767

2.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Authors:  Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

3.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

4.  Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy.

Authors:  J P Routy; M R Boulassel; C A Nicolette; J M Jacobson
Journal:  J Med Virol       Date:  2012-06       Impact factor: 2.327

5.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Authors:  Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje
Journal:  N Engl J Med       Date:  2015-02-05       Impact factor: 91.245

Review 6.  Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?

Authors:  G Pialoux; C Delaugerre; L Cotte; F Raffi; E Cua; J-M Molina
Journal:  Clin Microbiol Infect       Date:  2016-09-08       Impact factor: 8.067

7.  Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.

Authors:  Jared M Baeten; Deborah Donnell; Nelly R Mugo; Patrick Ndase; Katherine K Thomas; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Lara Kidoguchi; Robert W Coombs; Craig Hendrix; Mark A Marzinke; Lisa Frenkel; Jessica E Haberer; David Bangsberg; Connie Celum
Journal:  Lancet Infect Dis       Date:  2014-10-07       Impact factor: 25.071

8.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

Review 9.  Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.

Authors:  Raymond A Tetteh; Barbara A Yankey; Edmund T Nartey; Margaret Lartey; Hubert G M Leufkens; Alexander N O Dodoo
Journal:  Drug Saf       Date:  2017-04       Impact factor: 5.606

10.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321
View more
  7 in total

1.  Secondary HIV Infection and Mitigation in Cure-Related HIV Trials During Analytical Treatment Interruptions.

Authors:  Lynda Dee; Cheriko A Boone; David Palm; Danielle Campbell; Karine Dubé
Journal:  J Infect Dis       Date:  2019-08-30       Impact factor: 5.226

2.  Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.

Authors:  Jean-Daniel Lelièvre; Laurent Hocqueloux
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

3.  Is it ethical to isolate study participants to prevent HIV transmission during trials with an analytical treatment interruption?

Authors:  Nir Eyal; Monica Magalhaes
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

4.  Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.

Authors:  Karine Dubé; John Kanazawa; Lynda Dee; Jeff Taylor; Danielle M Campbell; Brandon Brown; Mallory O Johnson; Parya Saberi; John A Sauceda; Jeremy Sugarman; Michael J Peluso
Journal:  HIV Res Clin Pract       Date:  2021-03-24

5.  Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.

Authors:  Adam Gilbertson; Joseph D Tucker; Karine Dubé; Maartje Dijkstra; Stuart Rennie
Journal:  BMC Med Ethics       Date:  2021-12-28       Impact factor: 2.652

Review 6.  Applying the Behavioural and Social Sciences Research (BSSR) Functional Framework to HIV Cure Research.

Authors:  Karine Dubé; Judith D Auerbach; Michael J Stirratt; Paul Gaist
Journal:  J Int AIDS Soc       Date:  2019-10       Impact factor: 5.396

7.  Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.

Authors:  Jillian S Y Lau; Deborah Cromer; Mykola Pinkevych; Sharon R Lewin; Thomas A Rasmussen; James H McMahon; Miles P Davenport
Journal:  J Infect Dis       Date:  2022-08-24       Impact factor: 7.759
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.